BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical ...
Feb 27 (Reuters) - Minerva Neurosciences (NERV.O), opens new tab said on Tuesday the U.S. Food and Drug Administration (FDA) has declined to approve its drug to regulate behavioral changes in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback